Patients with newly diagnosed DLBCL were treated in a phase I study with R-CHOP (first cycle) followed by glofitamab-R-CHOP in subsequent cycles (6–8 cycles in total). The gene discussed is DDIT3; the disease is diffuse large B-cell lymphoma.